

## BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2020

Biohit Oyj Financial Statement Release 17 February 2021 at 9:30 am local time (EET)

### SUMMARY

January-December 2020

- Revenue EUR 7.1 million (EUR 10.1 million)
- Revenue decreased by 29.1 % compared to 2019
- Operative EBITDA EUR -1.2 million (EUR +0.6 million)
- Cash at the end of the period EUR 1.0 million (EUR 1.3 million)
- Fair value of Genetic Analysis AS investment EUR 0.8 million (EUR 3.7 million 31 December 2019)
- Revenue from international operations 96.1 % (96.0%) of total revenue
- Equity ratio 80.8 % (83.9 %)

July-December 2020

- Revenue EUR 4.1 million (EUR 5.1 million)
- Revenue decreased by 18.6 % compared to H2/2019
- Operative EBITDA EUR -0.2 million (EUR +0.2 million)

### BIOHIT GROUP KEY FIGURES

	7-12/2020	7-12/2019	1-12/2020	1-12/2019
Revenue (MEUR)	4.1	5.1	7.1	10.1
EBITDA (MEUR)	-0.2	0.2	-1.2	0.6
Operative EBITDA (MEUR)	-0.2	0.2	-1.2	0.6
Operating profit/loss (MEUR)*	-1.1	-0.8	-3.2	-1.4
Profit/loss before taxes (MEUR)	-0.9	-0.7	-3.3	-1.2
Profit/loss for the period (MEUR)	-1.0	-0.8	-3.3	-1.4
Average number of personnel	44	46	45	46
Number of personnel at the end of the period	46	46	46	46
Equity ratio (%)	80.8%	83.9%	80.8%	83.9%
Earnings per share (EUR). Undiluted	-0.07	-0.05	-0.22	-0.09
Earnings per share (EUR). Diluted	-0.07	-0.05	-0.22	-0.09
Shareholders' equity per share (EUR)	0.58	0.97	0.58	0.97
Average number of shares during the period	15,045,593	15,045,593	15,045,593	15,005,253
Number of shares at the end of the period	15,045,593	15,045,593	15,045,593	15,045,593

\* In 2017 we capitalized the patent regarding divestment of Biohit Healthcare (Hefei) Co. Ltd. which is depreciated EUR 1.5 million annually until end of 2021

## **PRESIDENT AND CEO SEMI KORPELA:**

### ***Business recovered both in Europe and China in the second half of 2020***

The impact of the COVID-19 pandemic on Biohit's business in the second half of the 2020 was more moderate than in the first half of the 2020. Our business recovered both in Europe and in China. The Middle-East market was almost at a standstill during the second half of the year 2020.

Our revenue decreased by 29 % compared to 2019. Our revenue on the second half of 2020 was EUR 4.1 million and it decreased by 19 % compared to the second half of 2019. Operative EBITDA decreased to EUR -1.2 million (EUR +0.6 million) of which the second half of the year generated EUR -0.2 million (EUR +0.2 million). We reached EUR 0.7 million savings in fixed costs as a result of the cost savings actions taken by the company. We accounted EUR -0.2 million in provision of obsolete inventory relating to products which sales stopped at the beginning of the year due to pandemic. Our cash at the end of the period remained on a good level EUR 1.0 million (EUR 1.3 million) due to the company's effective working capital management. Cash flow from the operating activities was positive EUR +0.2 million during the second half of the year.

Comprehensive income for 2020 was very negatively impacted by the fair value change in the investment in not listed Genetic Analysis AS shares, EUR -2.9 million. The fair value change had no impact on the cash flow. The COVID-19 pandemic created an extra challenge on the Genetic Analysis AS financing round.

The pandemic has resulted in a shortage of components in some areas and the company has increased inventories for certain components in order to secure deliveries to distributors at the beginning of 2021.

### **Main agreements and GastroPanel® Quick Test**

Despite the pandemic we made international distribution agreements for different product groups during the year 2020. We signed an agreement over the distribution of GastroPanel® QuickTest with Concile GmbH in Germany. In Algeria Hydra pharm s.a.r.l is our new QuickTest distributor. We also signed the exclusive distribution agreement with TPX Medik for distribution of Biohit GastroPanel® test in Malaysia. We also extended our agreement with SOK for the distribution of Acetium lozenge in their co-operative stores. In addition we signed an extension contract with GrandPharma for Acetium capsule production and distribution locally in China.

An important achievement during the review period was the new manufacture and licensing agreement with Biohit's long term distributor Melon OOO regarding local GastroPanel® production in Russia. The local production enables better utilization of Russia's Ministry of Health recommendation for early detection of gastrointestinal diseases. Business in Russia grew compared to the previous year despite the COVID-19 impact.

The development of the GastroPanel® Quick Test has been suspended since the beginning of the year 2020 due to the COVID-19 pandemic. The study will continue when the safety conditions for running the study can be secured. It is priority for Biohit to secure the safety of both its own personnel and partners in all operations including clinical studies. We estimate that the study will restart in the first quarter of 2021. The product will be CE marked as soon as the clinical trials are completed.

I want to thank all our stakeholders for good co-operation in 2020. Special thanks to the Biohit personnel for the excellent performance during this exceptional year.

## OUTLOOK FOR 2021

Biohit expects its 2021 revenue to grow significantly comparing with 2020 (previous year EUR 7.1 million).

The COVID-19 pandemic still creates uncertainty for the 2021 outlook. More information on the risks can be found in the section “short-term risks and uncertainty factors”.

## REPORTING

Biohit's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound, monoclonal antibodies, as well as laboratory operations for research and development. The entire product and service portfolio is reported under a single segment.

## REVENUE AND RESULT

### January-December

#### Consolidated revenue and operating profit

	7-12/2020	7-12/2019	Change	1-12/2020	1-12/2019	Change
Revenue MEUR	4.1	5.1	-0.9	7.1	10.1	-2.9
Change compared with the previous year (%)	-18.6%	1.5%		-29.1%	1.2%	
Operating profit/loss MEUR	-1.1	-0.8	-0.3	-3.2	-1.4	-1.8
Operating income (% of revenue)	-27.6%	-16.4%		-44.6%	-14.0%	

## REVENUE BY MARKET AREA

EUR million	7-12/2020	7-12/2019	1-12/2020	1-12/2019
Finland	0.1	0.2	0.3	0.4
Europe. other	1.9	2.0	3.6	4.0
North and South America	0.1	0.1	0.2	0.2
Asia	1.7	1.9	2.4	3.9
Other countries	0.3	0.9	0.6	1.6
<b>Revenue from contracts with customers</b>	<b>4.1</b>	<b>5.1</b>	<b>7.1</b>	<b>10.1</b>

## ALTERNATIVE PERFORMANCE MEASURES

### Bridge calculation of operative EBITDA

EUR million	7-12/2020	7-12/2019	1-12/2020	1-12/2019
<b>Operating profit/loss</b>	<b>-1.1</b>	<b>-0.8</b>	<b>-3.2</b>	<b>-1.4</b>
Depreciation and amortization	1.0	1.0	2.0	2.0
<b>Operative EBITDA</b>	<b>-0.2</b>	<b>0.2</b>	<b>-1.2</b>	<b>0.6</b>

## BALANCE SHEET, FINANCING AND OPERATIONAL CONTINUITY

On the 31 December 2020 the balance sheet totalled EUR 10.8 million (EUR 17.4 million 31 Dec 2019). At the end of the reporting period our equity ratio stood at 80.8 % (83.9% 31 Dec 2019).

The balance sheet have decreased mainly due to Hefei patents amortization by EUR 1.5 million, decrease in Genetic Analysis AS fair value by EUR 2.9 million, negative EBITDA EUR 1.2 million and decrease in the working capital EUR 1.3 million.

Biohit Oyj have relatively stable financing position despite the pandemic. On the 31 December 2020 company's financial assets totalled EUR 5.3 million (EUR 5.6 million) which does not include Genetic Analysis AS shares.

The company has managed to keep its working capital on a good level and the management believes that working capital will cover the operations for the next 12 months and the company is not dependent on external financing to be able to guarantee the continuity of its operations. Cash flow from operating activities was EUR -0.0 million during the review period and EUR +0.2 million during the second half of the year. Company's management assessment is that company's ability to continue its operations is good and there are no indications towards events or circumstances that alone or together might give a significant reason to doubt the organisation's ability to continue its operations.

## RESEARCH AND DEVELOPMENT AND CLINICAL STUDIES

R&D operations focus on innovations, as well as product development and further improved usability. Biohit also employs external experts and subcontractors in its R&D operations.

Development expenditure has not been capitalised. Research and development expenditure during the 1-12/2020 reporting period amounted to EUR 1.0 million (EUR 1.2 million) of which the second half-year accounted for EUR 0.5 million (EUR 0.6 million).

In July 2020 the results of a clinical study conducted by the Oulu University Hospital Gastrocenter and Outpatient Department of Internal Medicine in 2017-2020 were published in an international scientific journal in the field of gastroenterology. This study was focused on patients with type 1 diabetes mellitus (DM1) and autoimmune thyroid disease (AITD), who are known to have a markedly increased risk of contracting also autoimmune-type atrophic gastritis (gastric mucosal

atrophy and dysfunction). The result showed that atrophic gastritis is more common in AITD and DM1 patients compared to the general population and that the GastroPanel® is excellent test for early detection of gastric mucosal changes and the associated risks of gastric cancer and others in these patient groups.

The development of ColonView ELISA Test, automated screening test intended for detection of fecal occult blood (FOB) in stool samples have continued in 2020.

The status of GastroPanel® Quick Test is reported in CEO's comments section.

## **INVESTMENTS**

Gross investments during the the 1-12/2020 reporting period totalled EUR 0.0 million (EUR 0.0 million).

## **PERSONNEL**

During the review period the Biohit Group employed on average 45 (46) people of whom 36 (37) were employed by the parent company and 9 (9) by the subsidiaries.

## **SHORT-TERM RISKS AND UNCERTAINTY FACTORS**

Biohit's key risks are related to prolongation of coronavirus (SARS-CoV-2) pandemic, the success of product registrations, the selection and development of new market areas and distribution channels and personnel recruitment.

Significant short-term risks are associated with the normalization of Biohit's product demand and the success of product registration. The recent increase in uncertainty factors associated with international politics may have an unfavourable impact on the company's business. It is also critical in the short-term to implement the changes in Biohit's product portfolio and processes according to new EU regulation, 2021 (MDR) and 2022 (IVDR), so that the sales of the existing products can continue.

Prolongation of COVID-19 pandemic can increase bad debt risk among Biohit's international distribution network. The continuation of the shortage of components due to the COVID-19 pandemic may also have a negative impact on Biohit's sales.

The duration of the product registration process is different in each market area. For this reason, it is not possible to accurately assess the time taken for the authorities to handle registrations and for product sales to begin. The distributor is responsible for the registration process.

When investing liquid assets the objective is to gain a return on investment with a minimum risk of equity loss. The investment portfolio consists of deposits, money market investments and corporate loans. A fundamental aspect in portfolio management is sufficient diversification across different asset classes, investment instruments and counterparties. The investment portfolio is subject to interest rate risk, which is managed by adjusting the duration of the portfolio. In addition general instability in the financial markets impacts negatively on the value of the investment portfolio.

The Group's investment in Genetic Analysis AS unlisted shares is subject to changes in the terms of transactions involving the company's shares that take place between third parties. A negative change of 30 % in the valuation of Genetic Analysis AS shares would have a negative pre-tax impact of EUR 0.2 million on the Group comprehensive income. Investment in Genetic Analysis AS is also subject to changes in EUR/NOK foreign exchange rate. In addition Genetic Analysis AS is dependent on securing external financing in its operations. Genetic Analysis AS valuation changes have no effect on company's cash flow.

Biohit's customer base is widely diversified, with the exception of GastroPanel® sales in China, which currently represents a major single business for Biohit. For this reason the company is dependent on the success of this business in China. Otherwise the company is not significantly dependent on individual customers or project deliveries. Most of the company's business is conducted in euro and the indirect effects of currency exchange rate fluctuations are considered insignificant.

## **BOARD'S PROPOSAL FOR DISTRIBUTIONS OF PROFIT**

The parent company's distributable funds (unrestricted equity) on 31 December 2020 are EUR 5,905,188.50 of which the period net loss is EUR 3,350,126.90. The Board of Directors proposes to the Annual General Meeting that no dividend be paid for the fiscal year.

## **MAIN EVENTS IN THE SECOND HALF OF THE YEAR (H2)**

### **The usefulness of Biohit GastroPanel® biomarkers in diagnosis of atrophic gastritis confirmed in a multi-center study in France**

A significant confirmatory evidence to the previous studies on GastroPanel® biomarkers in diagnosis of atrophic gastritis and related gastric mucosal changes and associated gastric cancer and other risks was provided by a recently published multi-center study from France. This prospective multi-center study from a low-risk region of gastric cancer was conducted by the researches in the University Hospital of Nantes.

### **Decisions of the Annual General Meeting of Biohit Oyj**

The AGM resolved that seven (7) members are elected to the Board of Directors and that professor Osmo Suovaniemi, CEO Franco Aiolfi, emeritus professor Matti Härkönen, Commercial Counsellor Eero Lehti, Ph.D. Lea Paloheimo, CEO Liu Feng and professor Timo Joensuu are elected as members of the Board of Directors until the end of the next AGM.

### **Biohit GastroPanel® test applicability was studied clinically in patients with autoimmune disease**

This study was completed at the Outpatient Department of Internal Medicine (Oulu University Hospital), and the report of the results was recently accepted for publication in an international gastroenterology journal.

### **TPX Medik appointed as the exclusive distributor of GastroPanel® test in Malaysia**

Biohit Oyj and TPX Medik (Selangor, Malaysia) have signed a contract on the exclusive rights for distribution of Biohit GastroPanel® test in Malaysia. This is a major milestone in the global expansion strategy of Biohit Oyj's GastroPanel®.

## **MAJOR EVENTS AFTER THE CLOSE OF THE REVIEW PERIOD**

The company's management is not aware of any material events since the balance sheet date.

## ADMINISTRATION

### Biohit's financial reporting and Annual General Meeting in 2021

Biohit Oyj's Annual General Meeting has been planned to be held on Wednesday 21 April 2021 in Helsinki. The Board of Directors will call the General Meeting at a later date. In 2021 the company will publish the half-year financial report for period January - June 2021 (H1) at 9:30 am on Wednesday 11 August 2021.

### Biohit Oyj's Management Team

The members of Biohit's Management Team are: CEO Semi Korpela, CFO Jukka Kainulainen, Production & Research and Development Director Minna Mäki, Sales and Marketing Director Ilari Patrakka and Quality and Regulatory Affairs Director Daniela Söderström.

## SHARES AND SHAREHOLDERS

Biohit Oyj's number of shares is 15,045,593 (15,045,593), of which 2,975,500 (2,975,500) are Series A shares and 12,070,093 (12,070,093) are Series B shares. The Series B shares are quoted on NASDAQ Helsinki in the Small cap/Healthcare group under the code BIOBV.

BIOBV/NASDAQ OMX Helsinki	1-12/2020	1-12/2019
High (EUR)	4.30	3.70
Low (EUR)	1.90	2.10
Average (EUR)	2.56	2.99
Closing (EUR)	2.48	3.36
Turnover (EUR)	14,153,206	10,047,336
Turnover volume	5,518,054	3,361,995

### Shareholders

At the end of the reporting period on 31 December 2020 the company had 7,513 shareholders (6,980 on 31 December 2019). Private households held 63.3 % (63.5 %), companies 7.5 % (7.4 %) and public sector organisations 0.0 % (0.0 %). Foreign ownership or nominee registrations accounted for 29.2 % (29.1 %) of shares.

Further information on the shares, major shareholders and management shareholdings is available on the company's website.

## ACCOUNTING PRINCIPLES

This financial statement release has been prepared in accordance with the requirements of the IAS 34 Interim Financial Reporting standard. Biohit Oyj has applied the same accounting principles in preparing this financial statement release as for its financial statements 2019 except 2020 implemented IFRS standard changes and interpretations. Other changes in IFRS standards and interpretations has no material impact in this financial statement release. The figures in the financial statement release have not been audited.

### Alternative performance measures and items affecting comparability:

Biohit Group presents certain alternative performance measures to reflect the underlying business performance and to enhance comparability between financial periods according European Securities and Markets Authority, ESMA's guidance. Alternative performance measures should not be considered in isolation as a substitute for measures of performance in accordance with IFRS. Operative performance measures have been adjusted for certain non-operative items or non-cash valuation items that affect comparability between periods.

Certain items that are not related to the underlying business or non-cash valuation items that have material effect on the profit and loss for the period are adjusted as items affecting comparability. These items can arise for example from:

- Impairment of assets
- Sale or acquisition of asset or business
- Share based payment expenses in accordance with IFRS 2

Additionally Biohit Oyj presents the following alternative performance measures:

EBITDA                                      EBIT + depreciation and amortization

Operative EBITDA                      EBIT + depreciation and amortization – Items affecting comparability

## CONSOLIDATED INCOME STATEMENT

EUR million	7-12/2020	7-12/2019	Change	1-12/2020	1-12/2019	Change
<b>Revenue</b>	<b>4.1</b>	<b>5.1</b>	<b>-0.9</b>	<b>7.1</b>	<b>10.1</b>	<b>-2.9</b>
Change in inventories of finished goods and work in progress	0.0	0.1	-0.1	0.1	0.1	0.0
Other operating income	0.0	0.0	-0.0	0.0	0.0	-0.0
Materials and services	-1.9	-2.2	0.3	-3.3	-3.5	0.2
Employee benefit expenses	-1.5	-1.5	0.0	-3.1	-3.3	0.2
Other operating expenses	-1.0	-1.4	0.4	-2.1	-2.8	0.7
<b>EBITDA</b>	<b>-0.2</b>	<b>0.2</b>	<b>-0.3</b>	<b>-1.2</b>	<b>0.6</b>	<b>-1.8</b>
Depreciation and amortization	-1.0	-1.0	0.0	-2.0	-2.0	0.0
<b>Operating profit/loss</b>	<b>-1.1</b>	<b>-0.8</b>	<b>-0.3</b>	<b>-3.2</b>	<b>-1.4</b>	<b>-1.8</b>
Financial income	0.1	0.1	-0.0	0.1	0.2	-0.1
Financial expenses	0.1	0.0	0.1	-0.2	0.0	-0.2
<b>Profit/loss before taxes</b>	<b>-0.9</b>	<b>-0.7</b>	<b>-0.2</b>	<b>-3.3</b>	<b>-1.2</b>	<b>-2.0</b>
Income taxes	-0.0	-0.1	0.1	-0.1	-0.2	0.1
<b>Profit/loss for the financial period</b>	<b>-1.0</b>	<b>-0.8</b>	<b>-0.2</b>	<b>-3.3</b>	<b>-1.4</b>	<b>-1.9</b>
Items of comprehensive income that may later be reclassified through profit or loss						
Translation differences	0.0	0.0	0.0	-0.0	0.1	-0.1
Items that will not be reclassified to profit or loss						
Changes in the fair value of equity investments at fair value through other comprehensive income		-0.1	-0.1	-2.6	-0.1	-2.4
Other comprehensive income total	-0.0	-0.1	-0.1	-2.6	-0.1	-2.5
<b>Comprehensive income for the period</b>	<b>-1.0</b>	<b>-0.9</b>	<b>-0.1</b>	<b>-5.9</b>	<b>-1.5</b>	<b>-4.4</b>

### Earnings per share calculated from earnings attributable to the owners of the parent company

	1-12/2020	1-12/2019
Earnings per share (EUR), Undiluted	-0.22	-0.09
Earnings per share (EUR), Diluted	-0.22	-0.09

## CONSOLIDATED BALANCE SHEET

EUR million	31.12.2020	31.12.2019
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
Intangible assets	1.8	3.4
Property, plant and equipment	0.3	0.4
Right-of-use assets	0.4	0.3
Other financial long-term assets	0.1	0.1
Deferred tax assets	0.0	0.0
<b>Total non-current assets</b>	<b>2.5</b>	<b>4.2</b>
<b>CURRENT ASSETS</b>		
Inventories	0.9	1.0
Trade and other receivables	1.3	2.9
Other current financial assets	5.0	8.0
Cash and cash equivalents	1.0	1.3
<b>Total current assets</b>	<b>8.3</b>	<b>13.2</b>
<b>TOTAL ASSETS</b>	<b>10.8</b>	<b>17.4</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>		
Shareholders' equity attributable to the owners of the parent company		
Share capital	2.4	2.4
Fair value reserve	-1.2	1.4
Invested unrestricted equity fund	5.1	5.1
Translation differences	-0.1	-0.1
Retained earnings	2.5	5.8
<b>Total shareholders' equity</b>	<b>8.7</b>	<b>14.6</b>
<b>NON-CURRENT LIABILITIES</b>		
Lease liabilities	0.1	0.1
Deferred tax liabilities	0.0	0.4
Other liabilities	0.0	0.0
<b>Total non-current liabilities</b>	<b>0.1</b>	<b>0.4</b>
<b>CURRENT LIABILITIES</b>		
Trade payables	0.6	0.9
Tax liabilities	0.0	0.1
Lease liabilities	0.3	0.2
Other liabilities	1.0	1.2
<b>Total current liabilities</b>	<b>1.9</b>	<b>2.4</b>
<b>Total liabilities</b>	<b>2.1</b>	<b>2.8</b>

**TOTAL SHAREHOLDERS' EQUITY AND  
LIABILITIES****10.8****17.4****STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY****Statement of changes in consolidated shareholders' equity on 31 December 2020**

EUR million	Share capital	Invested unrestricted equity fund	Translation differences	Fair value reserve	Retained earnings	Shareholders' equity
Shareholders' equity 1 January 2020	2.4	5.1	-0.1	1.4	5.8	14.6
Total comprehensive income for the period			-0.0	-2.6	-3.3	-5.9
Shareholders' equity 31 December 2020	2.4	5.1	-0.1	-1.2	2.5	8.7

**Statement of changes in consolidated shareholders' equity on 31 December 2019**

EUR million	Share capital	Invested unrestricted equity fund	Translation differences	Fair value reserve	Retained earnings	Shareholders' equity
Shareholders' equity 1 January 2019	2.4	4.9	-0.1	1.5	7.3	15.9
Exercise of share options		0.2				0.2
Adjustments of translation differences					-0.1	-0.1
Total comprehensive income for the period			0.1	-0.1	-1.4	-1.5
Shareholders' equity 31 December 2019	2.4	5.1	-0.1	1.4	5.8	14.6

## FINANCIAL ASSETS MEASURED AT FAIR VALUE 31.12.2020

The Group categorised its financial assets and liabilities into the following categories	Fair value through profit and loss MEUR	Fair value through OCI MEUR	Hierarchical level
<b>Current assets</b>			
Other current financial assets	2.1		Level 1
Other current financial assets	2.0		Level 2
Other current financial assets	0.1		Level 3
Other current financial assets*		0.8	Level 3
<b>Total</b>	<b>4.2</b>	<b>0.8</b>	

\*In the 2020 financial statement the fair value of Genetic Analysis share, 0.8 MEUR, was valued based on the completed 3rd party transaction in a share issue of Genetic Analysis AS. The Genetic Analysis reached 3.2 MEUR financing in the share issue which decreased Biohit's shareholding from previous 12% to 8%. Biohit did not participate in the share issue.

## FINANCIAL ASSETS MEASURED AT FAIR VALUE 31.12.2019

The Group categorised its financial assets and liabilities into the following categories	Fair value through profit and loss MEUR	Fair value through OCI MEUR	Hierarchical level
<b>Current assets</b>			
Other current financial assets	1.3		Level 1
Other current financial assets	2.9		Level 2
Other current financial assets	0.1		Level 3
Other current financial assets		3.7	Level 3
<b>Total</b>	<b>4.3</b>	<b>3.7</b>	

The company has classified the hierarchies of financial assets according to the availability of data on market terms and other price data.

In significant part, the fair values of level 2 instruments are based on other input data than the quoted prices included in level 1, although this data can be obtained for the assets or liabilities in question either directly (as a price) or indirectly (as a derivative of the price). The Group uses generally accepted valuation models to determine the fair values of these instruments, and the input data for these models are based in significant part on observable market data.

The level in the fair value hierarchy at which a certain item measured at fair value is classified overall is determined on the basis of the significant input data on the lowest level with regard to the entire item measured at fair value. The significance of input data is evaluated in its entirety in relation to the item valued at fair value.

The book value of trade and other receivables and payables and cash and cash equivalents which are measured at amortised cost corresponds to their fair value due to their short maturities.

Other current financial assets on level 1 and 2 consists of fixed income funds and corporate loans. Other current financial assets on level 3 consists of the Group's investment in unlisted shares of Genetic Analysis AS. In addition one of the corporate loans is categorized on level 3 in year 2020.

## CASH FLOW STATEMENT

EUR million	7-12/2020	7-12/2019	Change	1-12/2020	1-12/2019	Change
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>						
Profit for the period	-1.0	-0.8	-0.2	-3.3	-1.4	-1.9
Adjustments	0.9	1.1	-0.2	2.1	1.9	0.1
Change in working capital	0.4	0.1	0.3	1.3	-0.4	1.7
Interest paid and payments on other operating financial expenses	-0.1	-0.0	-0.0	-0.1	-0.1	-0.1
Interest received	0.1	0.1	-0.0	0.1	0.1	-0.1
Realised exchange rate gains and losses	-0.0	0.0	-0.0	-0.0	0.0	-0.0
Income taxes paid	-0.1	-0.1	0.1	-0.1	-0.1	-0.0
<b>Net cash flow from operating activities</b>	<b>0.2</b>	<b>0.3</b>	<b>-0.1</b>	<b>-0.0</b>	<b>0.1</b>	<b>-0.1</b>
<b>CASH FLOW FROM INVESTMENTS</b>						
Investments in tangible and intangible assets	-0.0	-0.0	0.0	-0.0	-0.0	0.0
Investments in funds and deposits	-1.3	-0.0	-1.3	-1.6	-1.5	-0.1
Profit from the sale of investments in funds and deposits	1.3	0.0	1.3	1.5	1.5	0.1
Loans	0.0	0.0	0.0		-0.1	0.1
<b>Net cash flow from investments</b>	<b>-0.0</b>	<b>-0.0</b>	<b>-0.0</b>	<b>-0.0</b>	<b>-0.1</b>	<b>0.1</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>						
Share subscriptions with options	0.0	0.0	0.0		0.2	-0.2
Debt	0.0	0.0			0.0	-0.0
Repayment of lease liabilities	-0.1	-0.2	0.1	-0.2	-0.2	0.0
<b>Net cash flow from financing activities</b>	<b>-0.1</b>	<b>-0.2</b>	<b>0.1</b>	<b>-0.2</b>	<b>-0.0</b>	<b>-0.2</b>
Increase (+)/decrease (-) in cash and cash equivalents	0.1	-0.0	0.1	-0.3	-0.1	-0.2
Cash and cash equivalents at the beginning of the period	1.0	1.3	-0.3	1.3	1.4	-0.0
Effect of exchange rates on cash and cash equivalents	0.0	0.0	-0.0	-0.0	0.0	-0.0
<b>Cash and cash equivalents at the end of the period</b>	<b>1.0</b>	<b>1.3</b>	<b>-0.3</b>	<b>1.0</b>	<b>1.3</b>	<b>-0.3</b>

## RELATED PARTY TRANSACTIONS

Biohit Oyj sold EUR 2.1 million (EUR 3.6 million) worth of goods and services to Biohit Healthcare (Hefei) Co. Ltd during the review period. Biohit Oyj's total remuneration for the Board of Directors was EUR 0.3 million (EUR 0.3 million) during the review period. Remuneration for the companies under the control of the Board of Directors, BioAir S.pA and Biobrick, was EUR 0.1 million (EUR 0.1 million).

## COLLATERAL, CONTINGENT LIABILITIES AND OTHER COMMITMENTS

EUR million	31.12.2020	31.12.2019
<b>Collateral granted on behalf of the parent company</b>		
Guarantees	0.0	0.0
<b>Collateral and contingent liabilities total</b>	<b>0.0</b>	<b>0.0</b>

## NEXT FINANCIAL REPORT

The half-year financial report for January - June 2021 (H1) will be published at 9:30 am local time (EET) on Wednesday 11 August 2021.

## Helsinki 17 February 2021

Biohit Oyj  
Board of Directors

### Additional information:

CEO Semi Korpela  
tel. +358 9 773 861  
investor.relations@biohit.fi  
www.biohithealthcare.com

### *Biohit Oyj in brief*

*Biohit is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.*  
[www.biohithealthcare.com](http://www.biohithealthcare.com)